TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

被引：0
|
作者：
Jolanta Kupryjanczyk
Ewa Kraszewska
Izabela Ziolkowska-Seta
Radoslaw Madry
Agnieszka Timorek
Janina Markowska
Jerzy Stelmachow
Mariusz Bidzinski
机构：
[1] the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,Department of Molecular Pathology
[2] Medical Center for Postgraduate Education,Department of Gastroenterology and Hepatology
[3] the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,Department of Gynecologic Oncology
[4] Warsaw Medical University and Brodnowski Hospital,Department of Pathology, IInd Faculty of Medicine
[5] Medical University,Chair of Gynecologic Oncology
[6] Warsaw Medical University and Brodnowski Hospital,Chair and Department of Obstetrics, Gynecology and Oncology, IInd Faculty of Medicine
来源：
BMC Cancer | / 8卷
关键词：
Ovarian Cancer Patient; Clear Cell Carcinoma; Poor Tumor Differentiation; TP53 Status; TP53 Protein;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study
    He, Wei
    Zhang, Yan
    Xiong, Yu
    Dai, Feng-juan
    Fan, Qing-xia
    ONCOTARGETS AND THERAPY, 2016, 9 : 4037 - 4041
  • [42] BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer
    Kotsopoulos, Joanne
    Willows, Karla
    Trat, Sandra
    Kim, Raymond H.
    Volenik, Alexandra
    Sun, Ping
    Narod, Steven A.
    Boyd, Jeffrey
    May, Taymaa
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (01) : 69 - 76
  • [43] FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer
    Cortinovis, D. L.
    Andriani, F.
    Livio, A.
    Fabbri, A.
    Perrone, F.
    Marcomini, B.
    Pilotti, S.
    Mariani, L.
    Bidoli, P.
    Bajetta, E.
    Roz, L.
    Sozzi, G.
    CURRENT CANCER DRUG TARGETS, 2008, 8 (05) : 342 - 348
  • [44] Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer
    Nicoletto, M. O.
    Tumolo, S.
    Sorio, R.
    Cima, G.
    Endrizzi, L.
    Nascimben, O.
    Vinante, O.
    Artioli, G.
    Donach, M.
    Cartei, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (05) : 986 - 992
  • [45] Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy
    Thomas A. d’Amato
    Brian L. Pettiford
    Mathew J. Schuchert
    Ricardo Parker
    William A. Ricketts
    James D. Luketich
    Rodney J. Landreneau
    Annals of Surgical Oncology, 2009, 16 : 2848 - 2855
  • [46] Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics
    Madeddu, Clelia
    Lai, Eleonora
    Neri, Manuela
    Sanna, Elisabetta
    Gramignano, Giulia
    Nemolato, Sonia
    Scartozzi, Mario
    Giglio, Sabrina
    Maccio, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [47] Survival Among Patients with Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer Treated with Platinum-Based Systemic Therapy
    d'Amato, Thomas A.
    Pettiford, Brian L.
    Schuchert, Mathew J.
    Parker, Ricardo
    Ricketts, William A.
    Luketich, James D.
    Landreneau, Rodney J.
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (10) : 2848 - 2855
  • [48] A PHASE III TRIAL OF RH-ENDOSTATIN PLUS PLATINUM-BASED CHEMOTHERAPY VERSUS PLATINUM-BASED CHEMOTHERAPY IN PREVIOUSLY UNTREATED NON-SMALL CELL LUNG CANCER PATIENTS
    Zhou, J.
    Xiang, Y.
    Gao, B.
    Chen, W.
    Li, Q.
    Wan, H.
    RESPIROLOGY, 2011, 16 : 147 - 147
  • [49] Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?
    Macerelli, Marianna
    Ganzinelli, Monica
    Gouedard, Cedric
    Broggini, Massimo
    Garassino, Marina Chiara
    Linardou, Helena
    Damia, Giovanna
    Wiesmueller, Lisa
    CANCER TREATMENT REVIEWS, 2016, 48 : 8 - 19
  • [50] TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    Bonnefoi, Herve
    Piccart, Martine
    Bogaerts, Jan
    Mauriac, Louis
    Fumoleau, Pierre
    Brain, Etienne
    Petit, Thierry
    Rouanet, Philippe
    Jassem, Jacek
    Blot, Emmanuel
    Zaman, Khalil
    Cufer, Tanja
    Lortholary, Alain
    Lidbrink, Elisabet
    Andre, Sylvie
    Litiere, Saskia
    Dal Lago, Lissandra
    Becette, Veronique
    Cameron, David A.
    Bergh, Jonas
    Iggo, Richard
    LANCET ONCOLOGY, 2011, 12 (06): : 527 - 539
12345